F2G
F2G is a biopharmaceutical company developing novel antifungal therapies for patients with rare, life-threatening fungal infections. Its lead candidate, olorofim, is an oral antifungal that has completed a global Phase 3 study (OASIS) evaluating its efficacy against invasive aspergillosis, with positive topline results reported. The company also offers an early access program for patients in the US to access investigational therapies before regulatory approval.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Life-threatening fungal pathogens are increasingly developing resistance to existing antifungal treatments, leaving patients with rare and serious fungal infections with limited therapeutic options. The growing threat of antifungal resistance threatens to exhaust the current arsenal of treatments, creating an urgent need for novel approaches to combat these infections.
Solution
F2G is a biopharmaceutical company dedicated to developing effective antifungal therapies for patients fighting rare, life-threatening fungal infections. The company harnesses novel scientific approaches to create treatments that address the limitations of current antifungal options, with a focus on overcoming resistance mechanisms that render existing therapies ineffective. F2G's lead candidate, olorofim, is an oral antifungal being evaluated in late-stage clinical trials for invasive aspergillosis and other serious fungal diseases. The company maintains a patient-first ethos and a robust compliance program to ensure ethical conduct throughout its research and development activities.
Target Audience
Primary customers are patients with rare, life-threatening fungal infections and the healthcare professionals who treat them, including infectious disease specialists and clinical mycologists. The company also engages with regulatory agencies, research institutions, and pharmaceutical partners to advance antifungal drug development.
Features
- Novel science platform focused on developing antifungals with mechanisms designed to overcome resistance in life-threatening fungal pathogens
- Lead drug candidate olorofim, an oral antifungal in late-stage development (Phase 3 OASIS study) for invasive aspergillosis
- Dedicated early access program allowing patients in the US to access investigational therapies before regulatory approval
- Global operational footprint with headquarters in the UK, US, and Austria supporting international clinical development
- Corporate compliance program including an anonymous ethics hotline for reporting potential misconduct
- Medical information services providing healthcare professionals with product and safety data
- Partnerships and business development team focused on advancing the antifungal pipeline